

January 1, 2013

GROUP CHAIR'S OFFICE
Laurence H. Baker, DO
CHAIR

24 Frank Lloyd Wright Dr
PO Box 483
Ann Arbor, MI 48106

734-998-7130
734-998-7118 FAX

OPERATIONS OFFICE

4201 Medical Dr
Suite 250
San Antonio, TX 78229

210-614-8808
210-614-0006 FAX

STATISTICAL CENTER

1730 Minor Ave
Suite 1900
Seattle, WA 98101

206-652-2267
206-342-1616 FAX

1100 Fairview Ave North
M3-C102
PO Box 19024
Seattle, WA 98109

206-667-4623
206-667-4408 FAX

swog.org

TO: ALL SWOG MEMBER, CCOP AND AFFILIATE MEDICAL INVESTIGATORS AND CLINICAL RESEARCH ASSOCIATES

FROM: SWOG Operations Office

RE: Carboplatin Injection by Hospira, Inc.

IRB Review Requirements

- () Full board review required. Reason:
 - () Initial activation (should your institution choose to participate)
 - () Increased risk to patient
 - () Complete study redesign
 - () Addition of tissue banking requirements
 - () Study closure due to new risk information
- (√) Expedited review allowed
- () No review required

MEMORANDUM

Hospira, Inc. is further informing the general public about a previously communicated voluntary user-level recall of three lots of carboplatin injection due to visible particulates identified during a routine sample inspection. Findings have identified the particles as carboplatin crystals. If particulate matter from crystallization is injected into a patient, it may potentially become lodged in and obstruct blood vessels, potentially causing local infarction, thromboembolism and vasculitis. Chronically, following sequestration, granulomatous formation in the lungs is possible.

Anyone with an existing inventory should stop use and distribution, quarantine the product immediately, and call Stericycle at 877/650-8362 between the hours of 8am and 5pm EST, Monday through Friday, to arrange for the return of the product.

Read the complete MedWatch Safety Alert, including a link to the Recall Notice at: <http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm332358.htm>.